Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker (Q34929425)

5 August 2017

title

Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker (English)

1 reference

5 August 2017

1 reference

Rajan Dewar

1

1 reference

5 August 2017

Sing-Tsung Chen

2

1 reference

5 August 2017

Heather Yeckes-Rodin

3

1 reference

5 August 2017

Kenneth Miller

4

1 reference

5 August 2017

Roya Khosravi-Far

5

1 reference

5 August 2017

publication date

15 March 2011

1 reference

Cancer Biology and Therapy

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

552-558

1 reference

Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087959

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

8 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.11.6.14675

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21282974

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/CBT.11.6.14675

1 reference

5 August 2017

1 reference

5 August 2017

1 reference